Latest Safety News

Evolution Mining has delivered record cash flow for FY25, meeting its original production and cost guidance amid high metal prices, while setting a confident outlook for FY26 with continued strong cash generation expected.

Terrain Minerals has wrapped up an expanded nearly 5,000-meter gold drilling campaign at its Lightning and Monza prospects within the Smokebush Project, with assay results expected in August 2025.

MC Mining’s subsidiary, Uitkomst Colliery, has launched a strategic Turnaround Plan aimed at operational restructuring and cost reduction, positioning the mine for growth amid a challenging coal market.

Rio Tinto has appointed Simon Trott as its new Chief Executive, effective August 25, 2025, marking a leadership transition focused on operational excellence and shareholder value.

Syntara Limited has initiated dosing in its Phase 1c SATELLITE trial for a novel topical treatment targeting keloid scars, marking a significant step in addressing a $3.5 billion global market. The study, led by Professor Fiona Wood, will evaluate safety and early efficacy over three months.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

X2M Connect Limited has launched a $4.9 million capital raising through a Placement and Entitlement Offer to reduce debt and accelerate expansion in IoT, AI, and renewable energy markets.

St Barbara Limited reported a robust Q4 June 2025 with gold sales surging 34% and full-year production meeting guidance, supported by a strong cash position and improved safety metrics.

Orcoda Limited has locked in six new multi-year SaaS contracts with Australian community transport providers following a successful government-backed trial, pushing its annual recurring revenue to approximately $5 million.

Matsa Resources has officially commenced mining operations at its Devon Pit Gold Mine, with ore haulage to begin late July and first processing slated for mid-September 2025.

Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.

HITIQ Limited is set to debut its PROTEQT concussion management system in the UK on August 4, 2025, uniquely integrating with NHS 111 telehealth services to offer free medical guidance. This launch marks HITIQ’s first international consumer market entry and a strategic step in its global expansion.